Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER
2024-514355-16-01Phase 3Authorised
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised trial in acute respiratory distress syndrome (ARDS) comparing Pirfenidone (Esbriet) with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Ventilator-free days at day 28. Planned start Jan 2025; status: authorised.
02
Drugs
pirfenidone
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2024-514355-16-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514355-16-01.